['neovascular age-related macular degeneration']
['regn910-3', 'intravitreal aflibercept injection (iai)']

        Key Inclusion Criteria:

          1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including
             juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as
             assessed by a central reading center

          2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the
             study eye.

          3. Willing and able to comply with clinic visits and study-related procedures.

          4. Provide signed informed consent.

        Key Exclusion Criteria:

          1. Evidence of CNV due to any cause other than AMD in either eye

          2. Prior IVT anti-VEGF in the study eye

          3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in
             either eye in diabetic patients

          4. Any history of macular hole of stage 2 and above in the study eye
      